Cel-Sci Corporation (NYSEAMERICAN:CVM) Short Interest Down 65.6% in June

Cel-Sci Corporation (NYSEAMERICAN:CVM) was the target of a significant drop in short interest in June. As of June 30th, there was short interest totaling 263,542 shares, a drop of 65.6% from the June 15th total of 765,484 shares. Based on an average daily trading volume, of 424,964 shares, the days-to-cover ratio is currently 0.6 days. Currently, 1.7% of the shares of the stock are short sold.

Institutional Trading of Cel-Sci

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. State Street Corp boosted its holdings in Cel-Sci by 9.9% during the fourth quarter. State Street Corp now owns 25,570 shares of the company’s stock worth $134,000 after buying an additional 2,300 shares in the last quarter. US Bancorp DE acquired a new stake in shares of Cel-Sci during the 3rd quarter valued at $80,000. HighTower Advisors LLC acquired a new stake in shares of Cel-Sci during the 4th quarter valued at $53,000. HRT Financial LP bought a new stake in shares of Cel-Sci during the 4th quarter worth $60,000. Finally, XTX Topco Ltd bought a new stake in shares of Cel-Sci during the 4th quarter worth $66,000. 12.08% of the stock is owned by institutional investors and hedge funds.

Cel-Sci Price Performance

NYSEAMERICAN:CVM opened at $1.38 on Monday. The company has a quick ratio of 0.54, a current ratio of 0.60 and a debt-to-equity ratio of 0.64. The business’s 50-day moving average price is $1.34 and its 200 day moving average price is $3.39. Cel-Sci has a 52-week low of $0.89 and a 52-week high of $13.48. The firm has a market cap of $24.12 million, a P/E ratio of -0.14 and a beta of 0.64.

Cel-Sci (NYSEAMERICAN:CVM) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.67) earnings per share for the quarter.

Cel-Sci Company Profile

CEL-SCI Corporation is a biotechnology company focused on the development of immunotherapy products to treat cancer and infectious diseases. Founded in 1983 and headquartered in Vienna, Virginia, the company applies its proprietary LEAPS® (Ligand Epitope Antigen Presentation System) and Multikine® immunotherapy platforms to stimulate the body’s immune response against disease. CEL-SCI operates as a clinical-stage enterprise, working to translate immunological insights into therapeutic candidates.

The company’s lead product candidate, Multikine (leukineferon), is an investigational immunotherapy designed to enhance the immune system’s ability to attack head and neck cancer cells.